Proteostasis Regulators in Cystic Fibrosis: Current Development and Future Perspectives

Area of Science:

• Molecular Biology
• Pharmacology
• Genetics

Background:

• Cystic fibrosis (CF) is characterized by the F508del mutation in the CF transmembrane conductance regulator (CFTR) protein.
• This mutation causes protein misfolding and premature degradation, impairing CFTR function.
• Current CFTR potentiators and correctors offer limited clinical benefit, necessitating novel therapeutic strategies.

Purpose of the Study:

• To review recent advancements in the discovery of CFTR proteostasis regulators.
• To discuss the design, chemical structure, and structure-activity relationships of these novel agents.
• To explore the potential of modulating the CFTR proteostasis environment for enhanced CF therapy.

Main Methods:

• Literature review of recent research on CFTR proteostasis regulators.
• Analysis of drug design, chemical structures, and structure-activity relationships.
• Discussion of therapeutic opportunities and challenges in the field.

Main Results:

• Several novel CFTR proteostasis regulators have been identified.
• These agents show promise in enhancing the efficacy of existing CFTR-targeting drugs.
• Understanding structure-activity relationships is crucial for optimizing therapeutic potential.

Conclusions:

• Modulating CFTR proteostasis represents a promising avenue for improving cystic fibrosis treatment.
• Further research into CFTR proteostasis regulators is warranted to overcome current therapeutic limitations.
• This field offers significant opportunities for developing more effective CF therapies.